BACKGROUND: Catechol-O-methyl transferase (COMT) is a candidate gene for schizophrenia with a role in dopamine metabolism, particularly in frontal cortex. COMT is within the region commonly deleted in 22q11 deletion syndrome (22q11DS), a syndrome with high prevalence of schizophrenia. We examined the role of COMT in schizophrenia-related expression in 22q11DS. METHODS: We genotyped the COMT functional Val(158/108)Met allele in 73 Caucasian adults with 22q11DS (36 men, 37 women; aged 33.8, SD 10.1 years; 37 Met, 36 Val hemizygosity) blind to clinical data and assessed effects on symptoms and frontal functioning. RESULTS: The lower activity Met allele was not significantly more prevalent than the Val allele in 33 subjects with schizophrenia. Excitement symptoms were more severe, however, and three frontal cognitive tests (theory of mind, Trails B, and olfactory identification), communication, and social functioning measures showed significantly worse performance with Met allele hemizygosity, even after accounting for effects of schizophrenia. CONCLUSIONS: The results suggest that hemizygosity of the COMT functional allele exerts an effect on some measures of frontal functioning in 22q11DS. Elevated levels of tonic dopamine activation associated with the COMT Met allele may underlie these aspects of expression. We must look elsewhere for causes of the high prevalence of schizophrenia in 22q11DS, however.
BACKGROUND:Catechol-O-methyl transferase (COMT) is a candidate gene for schizophrenia with a role in dopamine metabolism, particularly in frontal cortex. COMT is within the region commonly deleted in 22q11 deletion syndrome (22q11DS), a syndrome with high prevalence of schizophrenia. We examined the role of COMT in schizophrenia-related expression in 22q11DS. METHODS: We genotyped the COMT functional Val(158/108)Met allele in 73 Caucasian adults with 22q11DS (36 men, 37 women; aged 33.8, SD 10.1 years; 37 Met, 36 Val hemizygosity) blind to clinical data and assessed effects on symptoms and frontal functioning. RESULTS: The lower activity Met allele was not significantly more prevalent than the Val allele in 33 subjects with schizophrenia. Excitement symptoms were more severe, however, and three frontal cognitive tests (theory of mind, Trails B, and olfactory identification), communication, and social functioning measures showed significantly worse performance with Met allele hemizygosity, even after accounting for effects of schizophrenia. CONCLUSIONS: The results suggest that hemizygosity of the COMT functional allele exerts an effect on some measures of frontal functioning in 22q11DS. Elevated levels of tonic dopamine activation associated with the COMT Met allele may underlie these aspects of expression. We must look elsewhere for causes of the high prevalence of schizophrenia in 22q11DS, however.
Authors: Carrie E Bearden; Abbas F Jawad; David R Lynch; John R Monterossso; Set Sokol; Donna M McDonald-McGinn; Sulagna C Saitta; Stacy E Harris; Edward Moss; Paul P Wang; Elaine Zackai; Beverly S Emanuel; Tony J Simon Journal: Child Neuropsychol Date: 2005-02 Impact factor: 2.500
Authors: Andreas Meyer-Lindenberg; Philip D Kohn; Bhaskar Kolachana; Shane Kippenhan; Aideen McInerney-Leo; Robert Nussbaum; Daniel R Weinberger; Karen Faith Berman Journal: Nat Neurosci Date: 2005-04-10 Impact factor: 24.884
Authors: M Karayiorgou; M A Morris; B Morrow; R J Shprintzen; R Goldberg; J Borrow; A Gos; G Nestadt; P S Wolyniec; V K Lasseter Journal: Proc Natl Acad Sci U S A Date: 1995-08-15 Impact factor: 11.205
Authors: Christina Zaleski; Anne S Bassett; Karen Tam; Andrea L Shugar; Eva W C Chow; Elizabeth McPherson Journal: Am J Med Genet A Date: 2009-03 Impact factor: 2.802
Authors: Jacob A S Vorstman; Eva W Chow; Roel A Ophoff; Herman van Engeland; Frits A Beemer; René S Kahn; Richard J Sinke; Anne S Bassett Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2009-04-05 Impact factor: 3.568
Authors: Carrie E Bearden; David C Glahn; Agatha D Lee; Ming-Chang Chiang; Theo G M van Erp; Tyrone D Cannon; Allan L Reiss; Arthur W Toga; Paul M Thompson Journal: Biol Psychol Date: 2008-02-23 Impact factor: 3.251
Authors: Ania M Fiksinski; Maude Schneider; Clodagh M Murphy; Marco Armando; Stefano Vicari; Jaume M Canyelles; Doron Gothelf; Stephan Eliez; Elemi J Breetvelt; Celso Arango; Jacob A S Vorstman Journal: Am J Med Genet A Date: 2018-09-08 Impact factor: 2.802
Authors: Vandana Shashi; Timothy D Howard; Matcheri S Keshavan; Jessica Kaczorowski; Margaret N Berry; Kelly Schoch; Edward J Spence; Thomas R Kwapil Journal: Psychiatry Res Date: 2010-05-20 Impact factor: 3.222
Authors: Anne S Bassett; Christian R Marshall; Anath C Lionel; Eva W C Chow; Stephen W Scherer Journal: Hum Mol Genet Date: 2008-09-20 Impact factor: 6.150